ABBV
Status-Quo-PlayerAbbVie
$206.47
-0.72%
as of 13 Apr
Power Core
AbbVie's moat is the institutional capability to manage blockbuster patent transitions while maintaining therapeutic category dominance.
Direction of Movement
Upward, Powered by the Replacement Franchise Reaching Maturity
ROC 200
+9.4%
ABBV
AbbVie
$206.47
-0.72%
as of 13 Apr
DCF Fair Value: $160.07
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.